2025 ED Migraine Treatment Update: Top Injectable Options

Research Summary

The American Headache Society has updated its guidelines for treating migraines in adults in emergency departments, as detailed in a 2025 paper in the journal Headache. The review included 26 new randomized controlled trials assessing 20 injectable treatments. Prochlorperazine IV and greater occipital nerve blocks (GONB) are strongly recommended (level A) for eligible adults, while hydromorphone IV is strongly advised against. Dexketoprofen IV, ketorolac IV, metoclopramide IV, sumatriptan SC, and supraorbital nerve blocks (SONB) are recommended (level B) when appropriate. Chlorpromazine IV, dexamethasone IV, and valproate IV may be offered (level C), while paracetamol IV is discouraged. Further research is needed for other treatments.

Study Details

📄 Title: 2025 guideline update to acute treatment of migraine for adults in the emergency department: The American Headache Society evidence assessment of parenteral pharmacotherapies.

👥 Research Team: Robblee J et al.

📚 Published In: Headache

📅 Publication Date: 2025 Dec 1

⚕️ Medical Disclaimer: This summary is generated automatically from recent migraine research. Always consult with healthcare professionals for medical advice.